Clinical Trial Update: Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating an anti-CD30 bispecific antibody (AATC) in relapsed/refractory CD30-positive hematologic malignancies; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Cutaneous T-cell Lymphoma
• Diffuse Large B-cell Lymphoma
• Hodgkin Lymphoma
• Immunoblastic T-cell Lymphoma
• Leukemia

Drugs mentioned

• Anti-CD30 bispecific antibody AATC (AATC)

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Hodgkin Disease, CD30-Positive Diffuse Large B-Cell Lymphoma | Phase 1 | Status: RECRUITING